95 results on '"Borer, Jeffrey S"'
Search Results
2. Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the PRECISION Trial)
3. Sample Size Requirements for Clinical Trials of Transcatheter Valve Replacement and Valve Repair Devices
4. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen
5. Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes
6. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial
7. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease
8. Misconceptions and Facts About Mitral Regurgitation
9. Update on ivabradine for heart failure
10. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial)
11. Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction
12. Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients With Chronic Heart Failure
13. Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease
14. Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates
15. Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the SHIFT Study)
16. Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients
17. Usefulness of Preoperative Exercise Tolerance to Predict Late Survival and Symptom Persistence After Surgery for Chronic Nonischemic Mitral Regurgitation
18. Efficacy of Ivabradine, a Selective If Inhibitor, in Patients With Chronic Stable Angina Pectoris and Diabetes Mellitus
19. Acceptability and Psychometric Properties of the Minnesota Living With Heart Failure Questionnaire Among Patients Undergoing Heart Valve Surgery: Validation and Comparison With SF-36
20. Resting Heart Rate in Cardiovascular Disease
21. Risk of Cardiovascular Events in Patients Receiving Celecoxib: A Meta-Analysis of Randomized Clinical Trials
22. Prognostic Value of Exercise Tolerance Testing in Asymptomatic Chronic Nonischemic Mitral Regurgitation
23. The Epidemiology of Valvular Heart Disease: a Growing Public Health Problem
24. Cellular and Molecular Basis of Remodeling in Valvular Heart Diseases
25. Prognostic Impact of Systolic Hypertension on Asymptomatic Patients With Chronic Severe Aortic Regurgitation and Initially Normal Left Ventricular Performance at Rest
26. Development of cardiovascular drugs: The U.S. regulatory milieu from the perspective of a participating nonregulator
27. Severe mitral regurgitation due to mitral valve prolapse: risk factors for development, progression, and need for mitral valve surgery
28. Myocardial Connexin43 Expression in Left Ventricular Hypertrophy Resulting from Aortic Regurgitation
29. Application of Transcatheter Repair to Tricuspid Regurgitation: Still Looking Through a Dark Glass
30. Academic perspectives on the United States food and drug administration's guidance for industry on diabetes mellitus
31. Iatrogenic Atrial Septal Defect After Mitral Valve Repair for Mitral Regurgitation: To Close or Not to Close, That Is the Question
32. Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?
33. Cracking the NNT Code: Effect of Ivabradine on Recurrent Hospitalizations
34. Effect of Comorbidities and Risk Factors on Outcomes and Ivabradine’s Effects in Patients With Chronic Systolic Heart Failure in the SHIFT Trial
35. Effects of Heart Rate Reduction in Black Patients from the SHIFT (Systolic Heart Failure treatment with the If Inhibitor Ivabradine Trial) Study
36. The Editor’s Roundtable: Cardiac Valve Surgery
37. Medical misinformation: Vet the message!
38. PLASMA TRAIL AND OSTEOPROTEGERIN IN AR, AS AND STABLE CAD: RELATION TO CARDIAC GEOMETRY AND SYMPTOM STATUS
39. VASODILATING DRUGS PROVIDE NO CLINICAL BENEFIT FOR PATIENTS WITH CHRONIC NONISCHEMIC MITRAL REGURGITATION
40. WOMEN HAVE GREATER MID-TERM QUALITY OF LIFE BENEFIT THAN MEN AFTER VALVULAR SURGERY
41. TRENDS IN RHEUMATIC VALVULAR HEART DISEASE: A LONGITUDINAL STUDY OF HOSPITALIZATIONS AND THE EFFECT OF IMMIGRATION IN NEW YORK CITY (1983-2007)
42. BIOMARKERS OF EXTRACELLULAR MATRIX IN LOW FLOW, LOW GRADIENT AORTIC STENOSIS: RELATIONSHIP TO HEMODYNAMIC, FUNCTIONAL, AND CLINICAL OUTCOMES - RESULTS FROM THE MULTICENTER TOPAS (TRULY OR PSEUDO SEVERE AORTIC STENOSIS) STUDY
43. Reply
44. Equilibrium radionuclide angiocardiography
45. Emerging Clinical Challenges in the Use of Statins
46. Left ventricular hypertrophy in hypertrophic cardiomyopathy: What's in a phenotype?
47. 1067-140 Subnormal tissue inhibitor of metalloproteinase expression modulates matrix metalloproteinase-2 activity and fibrosis in aortic regurgitation
48. 1048-139 Impact of associated coronary disease on hospital survival of patients with valvular heart disease in New York State (1983–2000)
49. 1067-135 Over-expression of fibronectin involves activation of mitogen-activated protein-kinase-kinase of the stress activated protein kinase/C-jun N-terminal kinase in aortic regurgitation
50. 1030-135 Impact of wide pulse pressure with and without high systolic blood pressure on clinical outcomes in chronic severe aortic regurgitation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.